Similar results have been shown for loss of ESE2 in both breast and prostate cancer, identifying also a prognostic value linked to its expression in cancer tissues (Feldman et al., 2003; Li et al., 2017; Watson et al., 2010; Yao et al., 2015). Here, ELF5 is linked to prostate carcinoma.